A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Biogen Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 432,842 shares of BIIB stock, worth $84.2 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
432,842
Previous 570,533 24.13%
Holding current value
$84.2 Million
Previous $123 Million 18.44%
% of portfolio
0.26%
Previous 0.33%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$190.52 - $236.72 $26.2 Million - $32.6 Million
-137,691 Reduced 24.13%
432,842 $100 Million
Q1 2024

May 08, 2024

BUY
$212.02 - $267.71 $25.9 Million - $32.7 Million
122,101 Added 27.23%
570,533 $123 Million
Q4 2023

Feb 09, 2024

SELL
$222.59 - $267.94 $47.2 Million - $56.8 Million
-212,114 Reduced 32.11%
448,432 $116 Million
Q3 2023

Nov 13, 2023

BUY
$253.3 - $285.89 $27.6 Million - $31.1 Million
108,841 Added 19.73%
660,546 $170 Million
Q2 2023

Aug 08, 2023

BUY
$275.25 - $318.06 $39.3 Million - $45.4 Million
142,793 Added 34.92%
551,705 $157 Million
Q1 2023

May 08, 2023

BUY
$256.56 - $292.34 $6.03 Million - $6.87 Million
23,502 Added 6.1%
408,912 $114 Million
Q4 2022

Feb 09, 2023

BUY
$252.44 - $306.72 $9.8 Million - $11.9 Million
38,818 Added 11.2%
385,410 $107 Million
Q3 2022

Nov 10, 2022

SELL
$194.69 - $268.46 $284,636 - $392,488
-1,462 Reduced 0.42%
346,592 $92.5 Million
Q2 2022

Aug 04, 2022

BUY
$187.54 - $223.02 $194,478 - $231,271
1,037 Added 0.3%
348,054 $71 Million
Q1 2022

May 12, 2022

BUY
$193.77 - $244.14 $20 Million - $25.2 Million
103,355 Added 42.42%
347,017 $73.1 Million
Q4 2021

Feb 09, 2022

SELL
$223.92 - $287.77 $13.3 Million - $17.1 Million
-59,318 Reduced 19.58%
243,662 $58.5 Million
Q3 2021

Nov 08, 2021

BUY
$282.99 - $369.05 $11.8 Million - $15.4 Million
41,710 Added 15.96%
302,980 $85.7 Million
Q2 2021

Aug 05, 2021

SELL
$259.0 - $414.71 $7.24 Million - $11.6 Million
-27,970 Reduced 9.67%
261,270 $90.5 Million
Q1 2021

May 05, 2021

BUY
$242.95 - $284.63 $7.41 Million - $8.69 Million
30,519 Added 11.8%
289,240 $80.9 Million
Q4 2020

Feb 12, 2021

BUY
$236.26 - $355.63 $1.99 Million - $2.99 Million
8,414 Added 3.36%
258,721 $63.4 Million
Q3 2020

Nov 09, 2020

BUY
$264.77 - $305.71 $24.8 Million - $28.6 Million
93,491 Added 59.62%
250,307 $71 Million
Q2 2020

Aug 04, 2020

SELL
$258.66 - $342.55 $3.11 Million - $4.12 Million
-12,034 Reduced 7.13%
156,816 $42 Million
Q1 2020

May 12, 2020

BUY
$268.85 - $341.04 $1.11 Million - $1.41 Million
4,128 Added 2.51%
168,850 $53.4 Million
Q4 2019

Feb 11, 2020

BUY
$220.06 - $304.07 $5.03 Million - $6.95 Million
22,849 Added 16.11%
164,722 $48.9 Million
Q3 2019

Nov 12, 2019

BUY
$217.44 - $243.88 $8.31 Million - $9.32 Million
38,227 Added 36.88%
141,873 $33 Million
Q2 2019

Aug 02, 2019

SELL
$219.29 - $241.72 $9.23 Million - $10.2 Million
-42,081 Reduced 28.88%
103,646 $24.2 Million
Q1 2019

Apr 26, 2019

BUY
$216.71 - $338.96 $5.48 Million - $8.57 Million
25,275 Added 20.98%
145,727 $34.4 Million
Q4 2018

Feb 13, 2019

BUY
$278.5 - $352.75 $3.29 Million - $4.17 Million
11,830 Added 10.89%
120,452 $35.4 Million
Q3 2018

Nov 13, 2018

BUY
$293.51 - $383.83 $4.57 Million - $5.98 Million
15,576 Added 16.74%
108,622 $38.4 Million
Q2 2018

Aug 01, 2018

SELL
$257.52 - $306.91 $4.66 Million - $5.56 Million
-18,107 Reduced 16.29%
93,046 $27 Million
Q1 2018

May 07, 2018

BUY
$260.13 - $367.91 $5.4 Million - $7.64 Million
20,757 Added 22.96%
111,153 $30.4 Million
Q4 2017

Feb 01, 2018

BUY
$307.64 - $344.58 $4.51 Million - $5.05 Million
14,655 Added 19.35%
90,396 $28.8 Million
Q3 2017

Nov 02, 2017

BUY
$281.15 - $329.69 $21.3 Million - $25 Million
75,741
75,741 $23.7 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $28B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Bnp Paribas Asset Management Holding S.A. Portfolio

Follow Bnp Paribas Asset Management Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.